^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Pancreatic Adenocarcinoma |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
The NCCN Panel recommends gemcitabine-erlotinib combination therapy as another option for patients with locally advanced or metastatic disease and good performance status, with this combination being a category 1 recommendation for patients with metastatic disease.
Secondary therapy:
gemcitabine
